Crown Bioscience Announces Promotion of Alex Slater to Chief Business Officer, Signaling Continued Focus on Commercial Excellence
SAN DIEGO—July 8, 2025—Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corporation, today announced the promotion of Alex Slater to Chief Business Officer, reinforcing the company’s commitment to advancing commercial excellence and client-centric growth.
Alex Slater has been with Crown Bioscience since 2021, most recently serving as Senior Vice President of Commercial, where he played a pivotal role in driving the company’s commercial strategy across APAC, EMEA, and the US. Throughout his tenure, Alex has led the business development function, helping to expand Crown Bioscience’s market presence and deliver innovative solutions to clients worldwide.
“Since joining Crown Bioscience, Alex has demonstrated strong leadership and strategic focus, successfully aligning our commercial organization to meet an evolving market,” said John Gu, CEO of Crown Bioscience. “His promotion reflects our confidence in his ability to drive continued growth and further strengthen client partnerships worldwide.”
Commenting on his appointment, Alex Slater said, “I’m honored to step into the Chief Business Officer role. Working alongside this exceptional team has been a privilege, and this milestone reflects the collective effort of everyone at Crown Bioscience. I look forward to building on our achievements as we continue to unlock new opportunities, deliver exceptional science, and expand our impact for clients and patients alike.”
The promotion comes as Crown Bioscience continues to strengthen in its global capabilities, including recent investments in laboratory infrastructure and the expansion of its preclinical platforms and service offerings.
For more information on the Crown Bioscience leadership, click here.
Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) dedicated to accelerating drug discovery and development in oncology and immuno-oncology. We partner with biotech and pharmaceutical companies to provide innovative, tailored solutions spanning preclinical research, translational platforms, and clinical trial support. With the world’s largest commercially available patient-derived xenograft (PDX) collection and approximately 1,000 tumor organoid models powered by Hubrecht Organoid Technology, we offer unparalleled insights across 35 cancer indications. Our expertise spans in vivo, in vitro, ex vivo, and in silico methods, complemented by advanced laboratory services that span the entire drug development continuum. Additionally, our extensive biobank of liquid and human biospecimens, complete with clinical histories, enhances oncology research capabilities. Operating from 11 state-of-the-art facilities across the US, Europe, and APAC, our laboratories meet the highest industry standards, including accreditation by the College of American Pathologists (CAP) and the International Organization for Standardization (ISO). To learn more, visit www.crownbio.com.
Contact details
-
- Sarah Martin-Tyrrell
-
Crown Bioscience Company Inquiries
Senior Manager, PR and Content - sarah.martin-tyrrell@crownbio.com
Related topics
Related news
Crown Bioscience Named Fierce CRO Award Winner for Excellence in Global Operations
Crown Bioscience, a JSR Life Sciences company, earns Fierce CRO Award for global operations excellence in oncology and immuno-oncology drug development services.
Crown Bioscience Achieves Green Lab Sustainability Certification
Crown Bioscience achieves 'Green' My Green Lab Certification in the Netherlands, highlighting leadership in sustainable lab best practices worldwide.
Crown Bioscience and NEXT Oncology Cement Partnership Extension
Crown Bioscience and NEXT Oncology renew collaboration, combining global clinical trial expertise and innovative cancer models for oncology drug development.
AACR 2025: Crown Bioscience Unveils 3D Bone Marrow Niche In Vitro Models for Oncology Preclinical Screening in Hemato...
Crown Bioscience launches 3D bone marrow niche in vitro models at AACR 2025, advancing predictive oncology screening for hematological malignancies.